- Home
- VRNA vs CORT Comparison
VRNA vs CORT Comparison
Compare VRNA & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- CORT
- Stock Information
- Founded
- VRNA 2005
- CORT 1998
- Country
- VRNA United Kingdom
- CORT United States
- Employees
- VRNA N/A
- CORT N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- VRNA Health Care
- CORT Health Care
- Exchange
- VRNA Nasdaq
- CORT Nasdaq
- Market Cap
- VRNA 8.3B
- CORT 8.8B
- IPO Year
- VRNA 2017
- CORT N/A
- Fundamental
- Price
- VRNA $106.91
- CORT $89.51
- Analyst Decision
- VRNA Buy
- CORT Strong Buy
- Analyst Count
- VRNA 11
- CORT 4
- Target Price
- VRNA $114.10
- CORT $139.00
- AVG Volume (30 Days)
- VRNA 1.5M
- CORT 917.9K
- Earning Date
- VRNA 11-03-2025
- CORT 10-29-2025
- Dividend Yield
- VRNA N/A
- CORT N/A
- EPS Growth
- VRNA N/A
- CORT N/A
- EPS
- VRNA N/A
- CORT 1.11
- Revenue
- VRNA $221,673,000.00
- CORT $716,080,000.00
- Revenue This Year
- VRNA $909.96
- CORT $30.77
- Revenue Next Year
- VRNA $76.47
- CORT $37.75
- P/E Ratio
- VRNA N/A
- CORT $81.04
- Revenue Growth
- VRNA N/A
- CORT 25.71
- 52 Week Low
- VRNA $31.09
- CORT $42.01
- 52 Week High
- VRNA $106.94
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- VRNA 72.60
- CORT 77.49
- Support Level
- VRNA $105.78
- CORT $82.70
- Resistance Level
- VRNA $106.86
- CORT $90.71
- Average True Range (ATR)
- VRNA 0.16
- CORT 2.60
- MACD
- VRNA -0.04
- CORT 0.78
- Stochastic Oscillator
- VRNA 98.26
- CORT 94.53
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.